Basics REGENXBIO Inc. Regenxbio Inc is a biotechnology company. It is engaged in the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. IPO Date: September 17, 2015 Sector: Healthcare Industry: Biotech Market Cap: $661.23M Activated in VL: True Average Daily Range Avg Daily Range: $0.78 | 2.89% Avg Daily Range (30 D): $0.36 | 3.34% Avg Daily Range (90 D): $0.29 | 3.05% Institutional Daily Volume Avg Daily Volume: .37M Avg Daily Volume (30 D): .48M Avg Daily Volume (90 D): .53M Trade Size Avg Trade Size (Sh.): 74 Avg Trade Size (Sh.) (30 D): 59 Avg Trade Size (Sh.) (90 D): 66 Institutional Trades Total Inst.Trades: 3,262 Avg Inst. Trade: $1.94M Avg Inst. Trade (30 D): $.85M Avg Inst. Trade (90 D): $1M Avg Inst. Trade Volume: .07M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.21M Avg Closing Trade (30 D): $.85M Avg Closing Trade (90 D): $.91M Avg Closing Volume: 82.18K     News Oct 6, 2025 @ 3:00 PM Viral Vector Gene Therapy Market Size Expects to R... Source: Towards Healthcare Jul 28, 2025 @ 5:00 PM Duchenne Muscular Dystrophy Market to Witness Sign... Source: Delveinsight May 21, 2025 @ 10:00 AM Coave Therapeutics Establishes New Scientific Advi... Source: N/A Mar 4, 2025 @ 3:55 PM 2025 Market Prospects of Adeno-Associated Virus Ve... Source: Researchandmarkets.Com Feb 21, 2025 @ 6:00 PM Cell and Gene Therapies in Rare Disorders Market t... Source: Delveinsight Financials   TTM Q2 2025 Q1 2025 Basic EPS $-3.43 $-1.38 $.12 Diluted EPS $-3.43 $-1.38 $.12 Revenue $ 155.78M $ 21.36M $ 89.01M Gross Profit $ $ $ Net Income / Loss $ -175.57M $ -70.87M $ 6.08M Operating Income / Loss $ -164.6M $ -63.28M $ 12.13M Cost of Revenue $ $ $ Net Cash Flow $ 21.79M $ -50.55M $ 72.58M PE Ratio